Epitope mapping of botulinum neurotoxins light chains

Toxicon

Volumn 60, Issue 7, 2012, Pages 1277-1286

  Zdanovsky, Alexey ^a   Zdanovsky, Denis ^a   Zdanovskaia, Maria ^a  

^a Alpha Universe LLC   (United States)

Author keywords

Antibody; Botulinum; Chimers; Epitope; Neurotoxin

Indexed keywords

ANTIBODY; BOTULINUM TOXIN; CARRIER PROTEIN; COSMETIC; DNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL WARFARE AGENT; DIAGNOSTIC VALUE; ENZYME ACTIVE SITE; EPITOPE MAPPING; FEMALE; LIGHT CHAIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; SEROTYPE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BOTULINUM TOXINS, TYPE A; EPITOPE MAPPING; FEMALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA;

EID: 84866498505     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2012.08.002     Document Type: Article

References (45)

1. Amersdorfer P., Wong C., Chen S., Smith T., Deshpande S., Sheridan R., Finnern R., Marks J.D. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Immun. 1997, 65:3743-3752.
2. Amersdorfer P., Wong C., Smith T., Chen S., Deshpande S., Sheridan R., Marks J.D. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 2002, 20:1640-1648.
3. Atassi M.Z. Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 2004, 19(Suppl. 8):S68-S84.
4. Atassi M.Z., Dolimbek B.Z., Hayakari M., Middlebrook J.L., Whitney B., Oshima M. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species. J. Protein Chem. 1996, 15:691-700.
5. Atassi M.Z., Dolimbek B.Z., Jankovic J., Steward L.E., Aoki K.R. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 2011, 216:782-792.
6. Atassi M.Z., Dolimbek G.S., Deitiker P.R., Aoki K.R., Dolimbek B.Z. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol. Immunol. 2005, 42:1509-1520.
7. Atassi M.Z., Jankovic J., Steward L.E., Aoki K.R., Dolimbek B.Z. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology 2012, 217:17-27.
8. Atassi M.Z., Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol. 1999, 19:219-260.
9. Atassi M.Z., Oshima M., Dolimbek B.Z., Aoki K.R. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Immunobiology 2012, 217:1-7.
10. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 2005, 73:6998-7005.
11. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., Barbieri J.T. Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 2008, 76:1314-1318.
12. Bavari S., Pless D.D., Torres E.R., Lebeda F.J., Olson M.A. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine 1998, 16:1850-1856.
13. Binz T., Kurazono H., Wille M., Frevert J., Wernars K., Niemann H. The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins. J. Biol. Chem. 1990, 265:9153-9158.
14. Brown D.R., Lloyd J.P., Schmidt J.J. Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin. Hybridoma 1997, 16:447-456.
15. Carruthers A., Kiene K., Carruthers J. Botulinum A exotoxin use in clinical dermatology. J. Am. Acad. Dermatol. 1996, 34:788-797.
16. Chen F., Kuziemko G.M., Amersdorfer P., Wong C., Marks J.D., Stevens R.C. Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect. Immun. 1997, 65:1626-1630.
17. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 2007, 44:1029-1041.
18. Dolimbek B.Z., Steward L.E., Aoki K.R., Atassi M.Z. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin. Immunobiology 2011, 216:698-706.
19. Dux M.P., Huang J., Barent R., Inan M., Swanson S.T., Sinha J., Ross J.T., Smith L.A., Smith T.J., Henderson I., Meagher M.M. Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastoris. Protein Expr. Purif. 2011, 75:177-185.
20. East A.K., Richardson P.T., Allaway D., Collins M.D., Roberts T.A., Thompson D.E. Sequence of the gene encoding type F neurotoxin of Clostridium botulinum. FEMS Microbiol. Lett. 1992, 75:225-230.
21. Hauser D., Eklund M.W., Kurazono H., Binz T., Niemann H., Gill D.M., Boquet P., Popoff M.R. Nucleotide sequence of Clostridium botulinum C1 neurotoxin. Nucleic Acids Res. 1990, 18:4924.
22. Kalb S.R., Baudis J., Rees J.C., Smith T.J., Smith L.A., Helma C.H., Hill K., Kull S., Kirchner S., Dorner M.B., Dorner B.G., Pirkle J.L., Barr J.R. De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. Anal. Bioanal. Chem. 2012, 403:215-226.
23. Levy R., Forsyth C.M., LaPorte S.L., Geren I.N., Smith L.A., Marks J.D. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol. 2007, 365:196-210.
24. Marks J.D. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov. Disord. 2004, 19(Suppl. 8):S101-S108.
25. Mullaney B.P., Pallavicini M.G., Marks J.D. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect. Immun. 2001, 69:6511-6514.
26. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U S A 2002, 99:11346-11350.
27. Oshima M., Middlebrook J.L., Atassi M.Z. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol. Lett. 1998, 60:7-12.
28. Pless D.D., Torres E.R., Reinke E.K., Bavari S. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect. Immun. 2001, 69:570-574.
29. Poulet S., Hauser D., Quanz M., Niemann H., Popoff M.R. Sequences of the botulinal neurotoxin E derived from Clostridium botulinum type E (strain Beluga) and Clostridium butyricum (strains ATCC 43181 and ATCC 43755). Biochem. Biophys. Res. Commun. 1992, 183:107-113.
30. Rosenberg J.S., Middlebrook J.L., Atassi M.Z. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol. Invest. 1997, 26:491-504.
31. Schantz E.J., Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 1992, 56:80-99.
32. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de Laureto P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
33. Schiavo G., Rossetto O., Benfenati F., Poulain B., Montecucco C. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann. N. Y. Acad. Sci. 1994, 710:65-75.
34. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., Montecucco C. Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 1992, 267:23479-23483.
35. Schiavo G., Santucci A., Dasgupta B.R., Mehta P.P., Jontes J., Benfenati F., Wilson M.C., Montecucco C. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993, 335:99-103.
36. Schiavo G., Shone C.C., Rossetto O., Alexander F.C., Montecucco C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J. Biol. Chem. 1993, 268:11516-11519.
37. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87:1044-1049.
38. Scott A.B., Kennedy R.A., Stubbs H.A. Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. 1985, 103:347-350.
39. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol. 2007, 27:303-318.
40. Smith T.J., Hill K., Foley B.T., Detter J.C., Munk A.C., Bruce D.C., Doggett N.A., Smith L.A., Marks J.D., Xie G., Brettin T.S. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3/Ba4 and/B1 clusters are located within plasmids. PLoS ONE 2007, 2:e1271.
41. Studier F.W., Moffatt B.A. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 1986, 189:113-130.
42. Thompson D.E., Hutson R.A., East A.K., Allaway D., Collins M.D., Richardson P.T. Nucleotide sequence of the gene coding for Clostridium barati type F neurotoxin: comparison with other clostridial neurotoxins. FEMS Microbiol. Lett. 1993, 108:175-182.
43. Wu H.C., Yeh C.T., Huang Y.L., Tarn L.J., Lung C.C. Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A. Appl. Environ. Microbiol. 2001, 67:3201-3207.
44. Yang G.H., Kim K.S., Kim H.W., Jeong S.T., Huh G.H., Kim J.C., Jung H.H. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon 2004, 44:19-25.
45. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., Yu W.Y., Sun Z.W. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.